Home » PhRMA Touts Robust Pipelines in Face of Patent Cliff Fallout
PhRMA Touts Robust Pipelines in Face of Patent Cliff Fallout
Drug company pipelines are more robust than ever, PhRMA announced Jan. 17 in releasing a report that counters fears the industry is losing its ability to innovate. The report emphasizes more than 5,000 drugs are in various clinical phases. Seventy percent are potential first-in-class drugs.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May